Stromal Therapeutics AG
|Category:||Emerging Biotech Company|
|Date:||April 25, 2023|
|Speaker:||Burkhard Ludewig, Founder and President of the Board|
Stromal Therapeutics AG is a Swiss biotech company founded in 2018, focused on developing immunotherapies against a broad range of chronic diseases by targeting the tissue stroma. Stromal Therapeutics lead compound targets cytokines that are involved in cardiac inflammation and fibrosis. Modulating the tissue stroma in cardiac inflammatory diseases is an innovative strategy to therapeutically target inflammatory heart disease, and potentially heart failure.